Vaccines, duration of protection: new ISS report, what has emerged

Vaccines, protection and efficacy over time: the results that emerged from the second report of the ISS and the Ministry of Health

The vaccine guarantees one protection from Covid “protracted over time”. The second report drawn up by the Istituto Superiore di Sanità puts it on paper (Iss) and by the Ministry of Health, which update that of 15 May and confirm the effectiveness of vaccination in the fight against the pandemic: thanks to the most recent data, it was possible to verify that 105-112 days after the first dose “a further reduction of the risk of diagnosis “.

The data communicated by the ISS confirm what was suggested by the first report about twenty days ago: “The risks of Sars-CoV-2 infection, hospitalization, admission to intensive care and death decrease rapidly” in individuals vaccinated against Covid-19, ” after the first two weeks and up to approximately 35 days after the first dose. After 35 days, a stabilization of this reduction is observed which is about 80% for the risk of diagnosis, 90% for the risk of hospitalization and admission to intensive care and 95% for the risk of death“.

The results of the recently published report give a more detailed account of the effects of vaccines in the long run. “From 105-112 days after vaccination, a further reduction in the risk of diagnosis is observed, with a similar effect in men, women and people in different age groups. There are currently no increases in the risk of diagnosis in the longer observation periods after vaccination, suggesting protracted protection over time, ”the report stresses.

The new report, which examined about 14 million people vaccinated with at least one dose, comes to an assessment more than 130 days after the administration of the first dose. Compared to the previous report, that of May 15, in the population studied there was an increase in vaccinated subjects in the age group from 40 years upwards. In addition, there is an increase in vaccinations with Comirnaty (Pfizer / BioNTech) and Vaxzevria (AstraZeneca) and the start of administration of the Janssen vaccine (Johnson & Johnson)

Virgil News | 06-06-2021 16:29

Photo source: ANSA

Covid, third dose: why it is needed, when and with which vaccine


Vaccines duration protection ISS report emerged

PREV A dip where water … costs so much more. Forte dei Marmi remains the refuge of the Scroogers
NEXT The real elections for the mayor of New York